Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Michaels, Samantha T.; Abruzzo, Todd A.; Augsburger, James J.; Corrêa, Zélia M.; Lane, Adam; Geller, James I.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 38:Issue 1(2016)
• Publication Date: 2016-01
• Subjects: retinoblastoma -- selective ophthalmic artery infusion chemotherapy -- vitreal seeds; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000000471
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Selective ophthalmic artery infusion chemotherapy (SOAIC) is increasingly used to treat retinoblastoma. We report the toxicities and outcome of 19 eyes in 17 patients with retinoblastoma receiving SOAIC treatment between 2008 and 2013. From the 87 treatments, mild local reactions were common. Myelosuppression was more common after triple-agent SOAIC (melphalan, carboplatin, and topotecan) than single-agent melphalan. Ocular salvage was achieved in 11 of 19 eyes and associated with triple-agent therapy. SOAIC is a effective therapy for some retinoblastoma with manageable toxicity; however, systemic toxicity increases with increasing therapeutic intensity of SOAIC.